Nifty
Sensex
:
:
16095.30
53876.13
-29.85 (-0.19%)
-176.48 (-0.33%)

Pharmaceuticals & Drugs - Global

Rating :
35/99

BSE: 524816 | NSE: NATCOPHARM

686.25
24-May-2022
  • Open
  • High
  • Low
  • Previous Close
  •  692.00
  •  697.70
  •  681.55
  •  703.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  459918
  •  3185.64
  •  1189.00
  •  645.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 12,542.59
  • 45.83
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 12,526.69
  • 0.76%
  • 2.91

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.81%
  • 4.16%
  • 17.47%
  • FII
  • DII
  • Others
  • 11.97%
  • 14.91%
  • 2.68%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.63
  • 0.31
  • -0.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.63
  • -2.45
  • -5.35

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 22.15
  • -1.93
  • -11.88

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 36.83
  • 26.32
  • 33.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.46
  • 4.39
  • 3.56

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.69
  • 19.58
  • 21.69

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Net Sales
560.50
355.20
57.80%
377.20
802.20
-52.98%
410.30
563.40
-27.17%
331.30
454.80
-27.15%
Expenses
458.70
272.70
68.21%
306.70
525.80
-41.67%
300.50
392.30
-23.40%
255.10
326.50
-21.87%
EBITDA
101.80
82.50
23.39%
70.50
276.40
-74.49%
109.80
171.10
-35.83%
76.20
128.30
-40.61%
EBIDTM
18.16%
23.23%
18.69%
34.46%
26.76%
30.37%
23.00%
28.21%
Other Income
30.20
30.80
-1.95%
38.00
25.70
47.86%
17.00
18.70
-9.09%
28.40
22.40
26.79%
Interest
5.00
3.40
47.06%
4.00
2.70
48.15%
2.00
3.70
-45.95%
3.50
3.50
0.00%
Depreciation
36.00
29.80
20.81%
34.70
28.70
20.91%
33.80
28.00
20.71%
30.40
30.50
-0.33%
PBT
91.00
80.10
13.61%
69.80
270.70
-74.21%
91.00
158.10
-42.44%
70.70
116.70
-39.42%
Tax
10.60
16.70
-36.53%
4.70
66.80
-92.96%
16.00
36.00
-55.56%
17.70
23.50
-24.68%
PAT
80.40
63.40
26.81%
65.10
203.90
-68.07%
75.00
122.10
-38.57%
53.00
93.20
-43.13%
PATM
14.34%
17.85%
17.26%
25.42%
18.28%
21.67%
16.00%
20.49%
EPS
4.41
3.45
27.83%
3.57
11.12
-67.90%
4.11
6.75
-39.11%
2.90
5.17
-43.91%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
1,679.30
2,052.10
1,915.00
2,094.50
2,184.80
2,020.20
1,141.30
825.28
738.89
660.53
523.72
Net Sales Growth
-22.81%
7.16%
-8.57%
-4.13%
8.15%
77.01%
38.29%
11.69%
11.86%
26.12%
 
Cost Of Goods Sold
319.10
483.70
354.40
332.70
411.10
599.10
341.10
242.37
233.23
242.80
203.08
Gross Profit
1,360.20
1,568.40
1,560.60
1,761.80
1,773.70
1,421.10
800.20
582.90
505.67
417.73
320.64
GP Margin
81.00%
76.43%
81.49%
84.12%
81.18%
70.34%
70.11%
70.63%
68.44%
63.24%
61.22%
Total Expenditure
1,321.00
1,448.30
1,332.40
1,299.70
1,256.40
1,336.80
868.70
611.90
559.56
510.60
414.38
Power & Fuel Cost
-
61.10
62.40
59.60
56.20
50.50
43.70
43.24
44.77
38.75
26.88
% Of Sales
-
2.98%
3.26%
2.85%
2.57%
2.50%
3.83%
5.24%
6.06%
5.87%
5.13%
Employee Cost
-
414.90
375.00
355.90
325.60
243.20
189.60
136.92
112.77
102.29
80.05
% Of Sales
-
20.22%
19.58%
16.99%
14.90%
12.04%
16.61%
16.59%
15.26%
15.49%
15.28%
Manufacturing Exp.
-
291.90
243.30
276.40
182.60
141.20
105.20
73.04
76.57
65.10
43.32
% Of Sales
-
14.22%
12.70%
13.20%
8.36%
6.99%
9.22%
8.85%
10.36%
9.86%
8.27%
General & Admin Exp.
-
116.70
132.60
126.40
105.50
88.10
73.40
63.66
56.21
39.49
32.37
% Of Sales
-
5.69%
6.92%
6.03%
4.83%
4.36%
6.43%
7.71%
7.61%
5.98%
6.18%
Selling & Distn. Exp.
-
34.40
98.10
90.00
136.90
143.20
91.60
37.36
26.16
14.82
19.02
% Of Sales
-
1.68%
5.12%
4.30%
6.27%
7.09%
8.03%
4.53%
3.54%
2.24%
3.63%
Miscellaneous Exp.
-
45.60
66.60
58.70
38.50
71.50
24.10
15.31
9.85
7.36
19.02
% Of Sales
-
2.22%
3.48%
2.80%
1.76%
3.54%
2.11%
1.86%
1.33%
1.11%
1.84%
EBITDA
358.30
603.80
582.60
794.80
928.40
683.40
272.60
213.38
179.33
149.93
109.34
EBITDA Margin
21.34%
29.42%
30.42%
37.95%
42.49%
33.83%
23.89%
25.86%
24.27%
22.70%
20.88%
Other Income
113.60
106.00
107.40
130.20
40.40
13.90
9.90
14.91
16.71
12.41
9.14
Interest
14.50
13.30
21.50
19.30
15.40
18.50
22.90
31.68
36.62
26.31
23.04
Depreciation
134.90
116.90
99.80
81.00
66.20
54.40
51.00
47.27
30.44
22.12
15.91
PBT
322.50
579.60
568.70
824.70
887.20
624.40
208.60
149.34
128.98
113.90
79.54
Tax
49.00
137.20
110.60
182.30
192.00
139.50
52.80
3.95
30.87
36.44
21.07
Tax Rate
15.19%
23.67%
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
23.93%
35.61%
26.49%
PAT
273.50
440.90
460.80
644.40
696.20
486.00
157.10
134.62
102.74
71.87
59.61
PAT before Minority Interest
273.50
442.40
458.10
642.40
695.20
484.90
155.80
130.27
98.11
65.88
58.47
Minority Interest
0.00
-1.50
2.70
2.00
1.00
1.10
1.30
4.35
4.63
5.99
1.14
PAT Margin
16.29%
21.49%
24.06%
30.77%
31.87%
24.06%
13.77%
16.31%
13.90%
10.88%
11.38%
PAT Growth
-43.33%
-4.32%
-28.49%
-7.44%
43.25%
209.36%
16.70%
31.03%
42.95%
20.57%
 
EPS
14.99
24.16
25.25
35.31
38.15
26.63
8.61
7.38
5.63
3.94
3.27

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
4,121.60
3,773.50
3,489.00
3,072.20
1,649.30
1,295.70
846.05
725.88
533.54
473.63
Share Capital
36.50
36.40
36.50
36.90
34.90
34.80
33.23
33.07
31.37
31.15
Total Reserves
4,067.60
3,713.60
3,421.70
3,011.40
1,599.00
1,251.20
812.82
692.80
502.17
442.49
Non-Current Liabilities
142.90
117.80
83.40
47.10
37.70
28.00
119.23
150.67
191.46
171.34
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
94.03
92.20
135.62
133.88
Unsecured Loans
0.90
0.90
0.00
0.00
0.00
0.00
2.99
3.28
2.21
0.22
Long Term Provisions
99.60
90.20
71.00
32.40
21.90
12.50
9.50
11.09
8.62
6.59
Current Liabilities
525.60
685.30
728.70
592.00
626.50
493.10
413.74
312.28
344.87
259.35
Trade Payables
146.20
255.40
217.00
269.10
262.70
275.60
125.30
109.79
105.85
92.36
Other Current Liabilities
98.60
95.90
109.80
133.40
127.10
114.20
118.56
102.18
90.21
81.91
Short Term Borrowings
266.70
315.00
386.30
173.20
221.60
98.40
168.54
98.63
147.74
81.64
Short Term Provisions
14.10
19.00
15.60
16.30
15.10
4.90
1.33
1.69
1.07
3.44
Total Liabilities
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.41
905.20
Net Block
2,023.20
1,584.40
1,227.20
1,018.60
833.00
710.10
709.97
644.74
582.75
319.56
Gross Block
2,702.10
2,148.70
1,694.50
1,407.60
1,158.70
983.30
939.98
819.89
726.97
440.33
Accumulated Depreciation
678.90
564.30
467.30
389.00
325.70
273.20
225.82
171.11
140.57
117.34
Non Current Assets
2,454.60
2,262.20
1,955.90
1,584.40
1,230.30
984.70
901.08
827.57
749.94
612.42
Capital Work in Progress
223.40
518.00
637.60
480.00
336.30
211.80
128.96
123.78
105.84
164.43
Non Current Investment
159.40
83.60
19.90
8.10
0.10
0.10
1.57
1.57
1.54
61.79
Long Term Loans & Adv.
44.30
72.00
62.80
75.40
60.40
62.10
57.03
54.25
57.20
66.22
Other Non Current Assets
4.30
4.20
8.40
2.30
0.50
0.60
3.54
3.24
2.61
0.42
Current Assets
2,337.30
2,325.60
2,347.20
2,130.70
1,087.30
837.00
482.97
368.14
330.48
292.79
Current Investments
144.30
28.70
148.70
68.40
32.10
22.10
0.12
0.32
0.81
0.74
Inventories
798.20
558.00
529.00
438.40
348.90
357.30
220.00
181.12
146.02
110.39
Sundry Debtors
412.90
551.30
506.20
637.50
475.20
261.60
192.43
118.80
129.71
94.69
Cash & Bank
283.50
66.00
279.50
183.70
35.80
45.20
13.36
11.05
10.78
36.63
Other Current Assets
698.40
91.60
107.40
53.20
195.30
150.80
57.06
56.85
43.14
50.34
Short Term Loans & Adv.
603.70
1,030.00
776.40
749.50
169.50
125.40
40.97
52.46
38.85
41.84
Net Current Assets
1,811.70
1,640.30
1,618.50
1,538.70
460.80
343.90
69.23
55.85
-14.39
33.44
Total Assets
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.42
905.21

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
298.80
417.30
668.80
463.60
345.80
112.20
92.67
144.03
61.19
64.94
PBT
579.60
568.70
824.70
887.20
624.40
208.60
134.22
128.98
102.32
79.54
Adjustment
62.10
54.00
14.30
75.60
100.20
90.50
68.14
65.72
48.87
36.97
Changes in Working Capital
-212.90
-97.60
8.60
-294.60
-253.00
-140.70
-85.96
-16.11
-67.39
-27.97
Cash after chg. in Working capital
428.80
525.10
847.60
668.20
471.60
158.40
116.41
178.58
83.80
88.54
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-130.00
-107.80
-178.80
-204.60
-125.80
-46.20
-23.74
-34.55
-22.61
-23.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-103.30
-167.00
-612.20
-1,115.50
-299.40
-175.50
-114.75
-108.92
-107.07
-126.94
Net Fixed Assets
-250.20
-335.80
-436.10
-392.40
-299.40
-303.91
-100.13
-99.70
-102.47
-151.51
Net Investments
-145.90
53.30
-94.80
-54.80
-1.00
37.47
-42.37
-11.33
-2.67
-3.71
Others
292.80
115.50
-81.30
-668.30
1.00
90.94
27.75
2.11
-1.93
28.28
Cash from Financing Activity
-185.70
-250.80
-50.90
650.90
-47.70
154.00
29.07
-35.27
26.31
62.78
Net Cash Inflow / Outflow
9.80
-0.50
5.70
-1.00
-1.30
90.70
6.99
-0.15
-19.57
0.78
Opening Cash & Equivalents
19.80
28.30
21.70
23.50
24.20
-164.10
10.22
9.95
34.64
31.70
Closing Cash & Equivalent
25.80
19.80
28.30
21.70
23.50
-74.20
12.44
10.22
9.95
34.64

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
224.88
206.04
189.49
165.22
93.63
73.91
50.91
219.48
170.06
152.06
ROA
9.43%
10.30%
16.02%
23.05%
23.43%
9.72%
10.10%
8.62%
6.64%
7.25%
ROE
11.27%
12.71%
19.75%
29.70%
33.21%
14.62%
16.57%
15.58%
13.08%
14.16%
ROCE
13.99%
14.82%
23.71%
35.28%
39.21%
18.04%
15.62%
18.02%
16.04%
15.72%
Fixed Asset Turnover
0.86
1.07
1.47
1.72
1.93
1.23
0.95
0.96
1.14
1.30
Receivable days
84.44
93.77
91.36
92.22
65.12
70.27
67.76
60.90
61.30
56.98
Inventory Days
118.77
96.38
77.28
65.25
62.41
89.35
87.33
80.17
70.04
73.13
Payable days
151.52
65.96
72.53
81.42
78.30
85.42
73.36
74.09
73.36
79.03
Cash Conversion Cycle
51.68
124.19
96.11
76.05
49.23
74.21
81.73
66.99
57.98
51.07
Total Debt/Equity
0.07
0.08
0.11
0.06
0.14
0.09
0.37
0.33
0.63
0.55
Interest Cover
44.58
27.45
43.73
58.61
34.75
10.11
5.24
4.52
4.89
4.45

News Update:


  • Natco Pharma, Arrow International launch first generic version of Revlimid in U.S. market
    8th Mar 2022, 10:52 AM

    Natco and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene

    Read More
  • Natco Pharma reports 27% rise in Q3 consolidated net profit
    16th Feb 2022, 11:30 AM

    Total consolidated income of the company increased by 53.03% at Rs 590.70 crore for Q3FY22

    Read More
  • Natco Pharma - Quarterly Results
    14th Feb 2022, 16:46 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.